- Home
- MFH vs TIL Comparison
MFH vs TIL Comparison
Compare MFH & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MFH
- TIL
- Stock Information
- Founded
- MFH 2011
- TIL 2018
- Country
- MFH United States
- TIL United States
- Employees
- MFH N/A
- TIL N/A
- Industry
- MFH Finance: Consumer Services
- TIL Biotechnology: Pharmaceutical Preparations
- Sector
- MFH Finance
- TIL Health Care
- Exchange
- MFH Nasdaq
- TIL Nasdaq
- Market Cap
- MFH 247.1M
- TIL 230.1M
- IPO Year
- MFH N/A
- TIL 2021
- Fundamental
- Price
- MFH $2.71
- TIL $31.69
- Analyst Decision
- MFH
- TIL Buy
- Analyst Count
- MFH 0
- TIL 5
- Target Price
- MFH N/A
- TIL $119.00
- AVG Volume (30 Days)
- MFH 1.8M
- TIL 263.6K
- Earning Date
- MFH 08-05-2025
- TIL 08-12-2025
- Dividend Yield
- MFH N/A
- TIL N/A
- EPS Growth
- MFH N/A
- TIL N/A
- EPS
- MFH N/A
- TIL N/A
- Revenue
- MFH N/A
- TIL N/A
- Revenue This Year
- MFH N/A
- TIL N/A
- Revenue Next Year
- MFH N/A
- TIL N/A
- P/E Ratio
- MFH N/A
- TIL N/A
- Revenue Growth
- MFH 125.92
- TIL N/A
- 52 Week Low
- MFH $1.03
- TIL $9.85
- 52 Week High
- MFH $8.86
- TIL $92.00
- Technical
- Relative Strength Index (RSI)
- MFH 40.87
- TIL 60.55
- Support Level
- MFH $1.56
- TIL $25.58
- Resistance Level
- MFH $3.61
- TIL $32.76
- Average True Range (ATR)
- MFH 0.87
- TIL 2.55
- MACD
- MFH -0.17
- TIL 0.75
- Stochastic Oscillator
- MFH 28.18
- TIL 89.55
About MFH Mercurity Fintech Holding Inc.
Mercurity Fintech Holding Inc is a New York-based digital fintech leader providing access to the rapidly growing AI-powered infrastructure, blockchain, and digital assets sectors. Its three core business lines include: 1. Blockchain and digital asset solutions. 2. AI and HPC infrastructure, specializing in developing liquid cooling solutions for AI data centers. 3. Comprehensive financial services.
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.